Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 479 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botulinum toxin type A (Btx-A) Clear all
Completed Phase 2 Interventional Results available

Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia

NCT04871451
View directory record Official record
Conditions
Cervical Dystonia
Interventions
ABP-450
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Fountain Valley, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

NCT02718118
View directory record Official record
Conditions
Glabellar Lines, Wrinkles
Interventions
Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Greenwood Village, Colorado • Coral Gables, Florida • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Dysport® Pediatric Lower Limb Spasticity Follow-on Study

NCT01251380
View directory record Official record
Conditions
Cerebral Palsy, Muscle Spasticity, Children
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Aurora, Colorado • Chicago, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

NCT02261493
View directory record Official record
Conditions
Facial Rhytides, Glabellar Rhytides
Interventions
OnabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

NCT00770029
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

NCT02706795
View directory record Official record
Conditions
Torticollis (Spasmodic)
Interventions
DaxibotulinumtoxinA
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Fountain Valley, California • Colorado Springs, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Spasmodic Dysphonia Pain

NCT04648891
View directory record Official record
Conditions
Spasmodic Dysphonia
Interventions
Lidocaine, Vibrating wand
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

NCT05167864
View directory record Official record
Conditions
Cosmetic Techniques
Interventions
Onabotulinumtoxina for Injection, Abobotulinumtoxina for Injection, IncobotulinumtoxinA for Injection, PrabotulinumtoxinA for Injection
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of OnabotulinumtoxinA (BOTOX®) on Stress

NCT06778421
View directory record Official record
Conditions
Stress (Psychology), Stress, Healthy Adult Female Participants, Stress, Psychologic, Stress, Psychological Cumulative, Stress, Physiological, Stress Response, Stress Levels, Stress Perception
Interventions
Intramuscular injection, OnabotulinumtoxinA (Botox®) Injections, Sodium Chloride
Procedure · Drug · Other
Lead sponsor
Center for Advanced Facial Plastic Surgery
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair

NCT02247193
View directory record Official record
Conditions
Cleft Lip, Scarring, Cleft Palate
Interventions
Botulinum Toxin Type A, Normal Saline Injection
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 6 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00907387
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
RT001, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children

NCT02106351
View directory record Official record
Conditions
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 14, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury

NCT00900666
View directory record Official record
Conditions
Stiff Knee Gait, Brain Injuries
Interventions
placebo, botulinum toxin A (BTX-A)
Drug
Lead sponsor
Mary Free Bed Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 14, 2026, 5:15 AM EDT
Terminated Phase 4 Interventional Results available

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

NCT01045694
View directory record Official record
Conditions
Arthritis Multiple Joint
Interventions
Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 14, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA

NCT02160535
View directory record Official record
Conditions
Chronic Post Traumatic Headache
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Endoscopic Gastric Reduction for Weight Management

NCT01682733
View directory record Official record
Conditions
Obesity
Interventions
Botulinum toxin, Overstitch Endoscopic Suturing System
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 14, 2026, 5:15 AM EDT
Terminated Phase 4 Interventional

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

NCT00477802
View directory record Official record
Conditions
Parkinson Disease
Interventions
Botulinum Toxin Type A, Placebo
Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2009 · Synced Oct 14, 2026, 5:15 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines

NCT04631588
View directory record Official record
Conditions
Facial Fine Lines
Interventions
Botox, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

NCT05152576
View directory record Official record
Conditions
Forehead Lines
Interventions
OnabotulinumtoxinA X, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Newport Beach, California • Mount Kisco, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 14, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine

NCT07571889
View directory record Official record
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

AI-09 In Subjects With Glabellar Lines, GL-101

NCT05565950
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AI-09, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
20 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Boca Raton, Florida • Miami, Florida • New Brighton, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain

NCT02221648
View directory record Official record
Conditions
Lower Back Pain
Interventions
Placebo, AbobotulinumtoxinA Treatment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 14, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00915525
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 14, 2026, 5:15 AM EDT